地舒单抗与BRCA1/2突变HR+/HER2-伴骨转移乳腺癌患者接受CDK4/6抑制剂后更长的真实世界无进展生存期相关:一项意大利多中心研究
这项回顾性多中心研究纳入1399例HR+/HER2-伴骨转移的转移性乳腺癌患者,其中46例携带胚系BRCA1/2突变。在BRCA1/2突变患者中,地舒单抗使用与更长的真实世界无进展生存期相关(中位35个月 vs 13个月;HR 0.34,95%CI 0.16-0.74;p=0.006),多变量分析证实该获益(调整HR 0.45,95%CI 0.21-0.99;p=0.048)。
要点
- 在BRCA1/2突变患者中,地舒单抗使用与rwPFS延长相关(中位35 vs 13个月)。
- 在BRCA1/2野生型/未知患者中,地舒单抗使用未影响rwPFS(HR 0.98)。
- 多变量分析确认BRCA1/2突变患者中地舒单抗的rwPFS获益(调整HR 0.45)。
核心结论
- 在真实世界队列中,地舒单抗使用与胚系BRCA1/2突变HR+/HER2-伴骨转移转移性乳腺癌患者更长的rwPFS相关。
研究设计与样本
- 回顾性多中心研究,纳入意大利24家医院接受一线或二线CDK4/6抑制剂联合内分泌治疗的HR+/HER2-伴骨转移转移性乳腺癌患者。
- 共纳入1399例患者,其中46例携带胚系BRCA1/2突变(13例BRCA1,33例BRCA2),21例接受地舒单抗。
主要发现
- 未接受地舒单抗的患者中,BRCA1/2野生型/未知患者的中位rwPFS优于BRCA1/2突变患者(28个月 vs 13个月;HR 0.48,95%CI 0.32-0.73;p=0.001)。
- BRCA1/2野生型/未知患者中,地舒单抗使用未影响rwPFS(HR 0.98,95%CI 0.85-1.12)。
- BRCA1/2突变患者中,地舒单抗使用与更长的rwPFS相关(中位35个月,95%CI 24-NR vs 13个月,95%CI 9-27;HR 0.34,95%CI 0.16-0.74;p=0.006),BRCA1与BRCA2突变亚组间无显著差异。
- 多变量分析证实BRCA1/2突变患者中地舒单抗的rwPFS获益(调整HR 0.45,95%CI 0.21-0.99;p=0.048)。
临床怎么用
- 对于携带胚系BRCA1/2突变的HR+/HER2-伴骨转移转移性乳腺癌患者,在接受CDK4/6抑制剂联合内分泌治疗时,可考虑使用地舒单抗以改善rwPFS。
局限性
- 本研究为回顾性研究,样本量有限(BRCA1/2突变患者仅46例,其中21例接受地舒单抗),可能存在选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical evidence suggests that BRCA1/2-mutated tumors may rely on RANKL signaling for survival and proliferation. RANKL inhibition with denosumab could disrupt tumor-bone microenvironment crosstalk and potentially limit metastatic progression. We evaluated the association between denosumab and real-world progression-free survival (rwPFS) in germline BRCA1/2-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) with bone metastases. METHODS: We performed a retrospective, multicenter study across 24 Italian hospitals including HR+/HER2- bone mBC patients treated in first- or second-line with a CDK4/6 inhibitor plus endocrine therapy. rwPFS was estimated by Kaplan-Meier and compared with log-rank tests. Center-stratified multivariable Cox models adjusted for clinically relevant covariates were used to assess the association between denosumab exposure and rwPFS. Effect modification by BRCA status was evaluated using a denosumab×BRCA1/2 mutation status. RESULTS: Among 1399 patients, 46 harbored germline BRCA1/2 mutations (13 BRCA1, 33 BRCA2), and 21 of these patients received denosumab. Among patients not receiving denosumab, BRCA1/2-wild-type/unknown patients had better rwPFS than BRCA1/2-mutated patients (median 28 vs 13 months; hazard ratio (HR) 0.48, 95% CI 0.32-0.73; p = 0.001). Among BRCA1/2-wild-type/unknown patients, denosumab use did not affect rwPFS (HR 0.98, 95% CI 0.85-1.12). Conversely, denosumab use was associated with longer rwPFS among patients with BRCA1/2 mutations (median 35 months, 95% CI 24-NR vs 13 months, 95% CI 9-27; HR 0.34, 95% CI 0.16-0.74; p = 0.006), with no significant difference between BRCA1 and BRCA2-mutated subgroups. Multivariable analysis confirmed the rwPFS benefit of denosumab in BRCA1/2-mutated patients (adjusted HR 0.45, 95% CI 0.21-0.99; p = 0.048). CONCLUSION: In this real-world cohort, denosumab use was associated with longer rwPFS in germline BRCA1/2-mutated HR+/HER2- mBC with bone metastases.
引用
- Scafetta R, Troiano R, Gullotta C, et al. Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study. Eur J Cancer. 2026. PMID: 41921366. doi:10.1016/j.ejca.2026.116703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。